Arm vein conduit vs prosthetic graft in infrainguinal revascularization for critical leg ischemia  by Arvela, Eva et al.
Arm vein conduit vs prosthetic graft in
infrainguinal revascularization for critical leg
ischemia
Eva Arvela, MD, Maria Söderström, MD, Anders Albäck, MD, PhD, Pekka-Sakari Aho, MD, PhD,
Maarit Venermo, MD, PhD, and Mauri Lepäntalo, MD, PhD, Helsinki, Finland
Background: One-piece great saphenous vein (GSV) is the conduit of choice in infrainguinal revascularizations for critical
limb ischemia (CLI). Unfortunately, adequate length of usable GSV is not always available. Despite inferior patency rates
compared with GSV, prosthetic and arm vein conduits are generally considered usable. The purpose of this study was to
compare the outcome of infrainguinal arm vein and prosthetic bypass.
Material and methods:We retrospectively reviewed 290 consecutive infrainguinal bypasses for CLI using arm vein conduit
(n  130) or prosthetic graft (n  160) during January 2000 and December 2006 at our institution. The groups were
compared for risk factors, indication for surgery, and runoff score. Survival, leg salvage, and patency rates were calculated
with the Kaplan-Meier method.
Results: Median surveillance time was 35 months (range 0-118 months). The age, gender, and usual risk factors were
similar in arm vein and prosthetic groups, except cerebrovascular disease that was more common in the prosthetic group
(P .011). Indication for surgery was CLI. In the arm vein group, more than two-thirds (70.2%) of the procedures were
for ischemic ulcer or gangrene, whereas in the prosthetic group the main indication was ischemic rest pain (51.3%). When
the outcome of femoropopliteal bypasses was analyzed, the difference between groups was not statistically significant.
However, in infrapopliteal revascularizations primary patency, assisted primary patency, and secondary patency rates at
3 years were significantly better in the arm vein group: 28.3% (SE  6.3%) vs 9.6% (SE  8.1%) (P  .031), 56.8% (SE
 6.6%) vs 10.4% (SE  8.7%) (P  .000), and 57.4% (SE  6.6) vs 11.2% (SE  9.3%) (P  .000), respectively. Leg
salvage and survival at 3 years were 75.0% (SE 4.9%) vs 57.1% (SE 8.8%) (P .005) and 58.8% (SE 5.1%) vs 39.5%
(SE  7.7%) (P  .007), respectively.
Conclusion: Arm vein conduits, even when spliced, are superior to prosthetic grafts in terms of midterm assisted primary
patency, secondary patency, and leg salvage in infrapopliteal bypasses for CLI. (J Vasc Surg 2010;52:616-23.)Single-segment great saphenous vein (GSV) is the pre-
ferred graft for infrainguinal revascularizations in terms of
long-term patency and limb salvage.1-3 However, due to
previous lower extremity bypasses, coronary artery bypass
grafting (CABG), or varicose vein surgeries, many patients
needing infrainguinal bypass lack GSV. Moreover, GSV
may be of poor quality due to small-caliber; varicosities or
postphlebitic changes. The reported incidence of absent
usable ipsilateral GSV is 20% to 45%.4-7 If usable ipsilateral
GSV is lacking, conduit options are alternative autologous
veins or prosthetic grafts. The use of prosthetic grafts in
above-knee femoropopliteal bypasses is widely accepted,
whereas in the infrapopliteal location, the role of prosthetic
bypasses remains controversial. Long- term patency of in-
frapopliteal prosthetic bypasses is poor or only moderate.8
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616On the other hand, there are groups reporting promising
short-term results using heparin-bonded or pre-cuffed
prosthetic grafts.9-12 However, autologous veins other
than GSV seem to be superior compared with prosthetic
grafts especially in infrapopliteal revascularizations in the
long term.3,13-16
The aim of this study was to assess the midterm out-
come of infrainguinal revascularizations in patients with
critical limb ischemia (CLI) when GSV is absent and to
compare results of arm vein bypasses with those achieved
with prosthetic grafts. The purpose was also to perform
subgroup analysis of infrapopliteal bypasses and to find out
whether the results of prosthetic bypasses to infrapopliteal
arteries are acceptable in terms of midterm patency and leg
salvage rates.
MATERIAL AND METHODS
The total number of all infrainguinal revascularizations
performed for CLI at our institution between January 1,
2000 and December 31, 2006 was 1353. We reviewed
retrospectively those 290 consecutive bypasses where either
arm vein (n  130) or prosthetic graft (n  160) was used
as a conduit.
Data were retrieved from a computerized vascular reg-
istry (Husvasc), which includes patient demographics, co-
morbid conditions, indications for surgery, specific opera-
tive details, complications, and outcome at discharge.
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revision or graft occlusion and dates of major amputation
or death. Dates of death and amputations were cross-
checked and if missing, retrieved from the Population
Registry Center and from National Institute of Health and
Welfare, respectively.
Indication for bypass surgery was CLI and only infrain-
guinal bypasses performed with arm veins or prosthetic
grafts were included.
The suitability of inflow and outflow arterial anatomy
for bypass was evaluated by magnetic resonance angiogra-
phy (MRA) or conventional digital subtraction angiogra-
phy (DSA). The angiograms were evaluated retrospec-
tively, and the runoff score was calculated using the grading
scheme proposed by Rutherford at al.17 We also evaluated
if there was an open direct line to foot arteries or not.
The size and quality of vein material to be used was
preoperatively mapped with ultrasonography. Our policy is
to use autologous vein grafts for infrainguinal revascular-
izations whenever possible. Of the available conduits, we
prefer to use the best available vein graft to treat the
immediate problem. Therefore, in the absence of ipsilateral
great saphenous vein (IGSV), the contralateral great saphe-
nous vein (CGSV) is our preferred conduit, unless the
donor limb is evidently ischemic.
Arm veins were used if usable GSV (ipsilateral or con-
tralateral) was absent. If the arm vein was not long enough,
spliced vein graft with two or more arm vein segments was
used. The operating surgeon decided whether the vein
graft was to be used in reversed or nonreversed configura-
tion. If spliced vein graft was used, reversed or nonreversed
vein segments were employed tominimize sizemismatch of
the vein-to-vein anastomoses and the conduit-to-artery
anastomoses. The vein-to-vein anastomoses were sutured
with 7-0 interrupted sutures. Minority of the spliced vein
grafts included also short segments of the lesser saphenous
vein (LSV) or the branch of GSV. However, as the grafts
mostly consisted of arm veins, the whole group is here
referred to as arm veins.
Prosthetic graft, either expanded polytetrafluoroethyl-
ene (ePTFE) or polyester (Dacron), was used if there were
no usable autologous veins available. In above-knee femo-
ropopliteal bypasses, prosthetic conduit was considered as
an alternative to arm veins except in the presence of infected
gangrene in affected limb. In other words, if indication of
surgery was rest pain, a prosthesis or arm vein was selected
to perform above-knee femoropopliteal bypass according
to the surgeon’s preference and the quality of available arm
veins. Overall health status of a patient also influenced the
conduit selection, as harvesting arm veins makes the proce-
dure longer and usually necessitates general anesthesia. If
the outflow vessel was the infrapopliteal artery (n 42), an
adjunctive vein cuff was used, except in cases where pre-
cuffed ePTFE prosthesis was used.
Transit time flow measurement was used to ensure
adequate graft flow (mL/min) at the end of the procedure.
The measurements were performed using a transit time
flowmeter (CardioMed CM4006; Medistim A/S, Oslo,Norway), which is based on an ultrasonic pulsed-beam
technique and measures volume flow within the conduit. A
precalibrated probe of right size to fit the conduit (normally
3-6 mm) is placed around the graft to measure the flow.
This method is found to be valid and reproducible, and it is
not dependent on vessel diameter or wall thickness.18,19 If
the graft flow was considered compromised, intraoperative
duplex scanning was performed to exclude graft segments
of inappropriate quality and technical defects in anastomo-
ses. Angioscopy or intraoperative angiography was used
selectively, not routinely. Threshold criteria for duplex or
angiography were the following: for femoropopliteal grafts,
rest flow150 mL/min; for crural bypasses, rest flow50
mL/min or maximum flow capacity (flow after injection of
40 mg papaverine) 110 mL/min; and for pedal recon-
structions, maximum flow capacity 45 mL/min.
Intraoperative heparin was administered to all patients
according to weight and adequacy of heparinization was
controlled using activated clotting time (ACT) assessment.
At the end of the procedure, heparin was antagonized.
Regardless of the graft material, all patients received
weight-adjusted doses of low-molecular-weight heparin
(LMWH) twice a day postoperatively until discharge and
ASA 100 mg per day indefinitely if there were no contrain-
dications (aspirin allergy). Some patients received clopi-
dogrel instead of aspirin (aspirin allergy, previous coronary
balloon angioplasty etc.). Warfarin was not routinely used
unless there was a clear indication (atrial fibrillation, trom-
bofilia etc.) for that. According to our institution’s antibi-
otic prophylaxis protocol, cefuroxime 1.5 g was given if the
patient received autologous conduit and cefuroxime 1.5 g
and vancomycin 1 g was administered if prosthetic graft was
used.
The follow-up visits were 1, 6, and 12 months postop-
eratively and thereafter annually. At each follow-up visit,
the evaluation protocol was the same including inspection
of the limb status, pulse palpation and measurement of
ankle-brachial indices (ABI) and toe pressures (TP). If arm
vein graft was used, duplex scanning of the entire graft was
performed. If duplex scanning revealed significant focal
stenosis (peak systolic velocity ratio 3 or overall graft
velocity 45 cm/s in a normal-caliber graft), angiography
was performed. The patency of prosthetic graft was ensured
by ABI and TPmeasurements and byDoppler auscultation.
The graft was considered patent if ABI remained improved
(0.15) compared with the preoperative value, and Dopp-
ler flow signal from at least two points over the graft was
audible. The duplex scanning of prosthetic bypass was
performed if the patency was uncertain, but we did not
routinely perform duplex for all prosthetic grafts.
The terms survival, leg salvage and the criteria for
patency and definitions of primary, assisted primary, and
secondary patency used in this study are those recom-
mended by the Ad Hoc Committee on Reporting Stan-
dards, SVS/NA-ISCVS.17 This retrospective study was ap-
proved by the Institutional Review Board of Helsinki
University Central Hospital.
ase; TI
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for surgery and runoff score. Student t-test was used for
continuous variables and 2 test was used for categorical
variables. Survival, leg salvage, and patency rates with mean
standard errors (SE) were calculated with the Kaplan-Meier
method for the whole study population and for femoro-
popliteal (above-knee and below-knee) and infrapopliteal
bypasses separately. Comparisons between patency curves
were assessed using a Mantel-Cox log-rank test for signifi-
cance. The predictive value of graft material and runoff
score for death and graft occlusion were also analyzed using
multivariate analyses. Differences were considered signifi-
cant if P value was .05. All statistical analyses were per-
formed using SPSS for Windows, version 17.0 (SPSS Inc.,
Chicago, IL).
RESULTS
A total of 290 infrainguinal bypasses using either arm
veins (n  130) or prosthesis (n  160) as a conduit were
performed over the 7-year study period. Median age of the
study population was 75 years (range, 41-95). There were
122 (42%) men and 168 (58%) women. Risk factors in-
cluded diabetes (39%), hypertension (74%), and coronary
artery disease (62%). Incidence of risk factors did not differ
between arm vein and prosthesis groups, except cerebro-
vascular disease, which was more common in the prosthetic
than in the arm vein group (P  .011). (Table I). Median
follow-up time was 35.3 months (range, 0.1-118.0).
One-third (32.5%) of the procedures were secondary
bypasses performed after failed previous reconstructions.
More than half of the bypasses (56%) were urgent proce-
dures, which means that bypass was performed in 72 hours
from the patient’s admission to the hospital, as the severity
of leg ischemia did not allow waiting the scheduled (ie,
elective) operation date. In all cases, the indication for
surgery was leg salvage (rest pain, 41%; ulcer or gangrene,
Table I. Demographics by graft material
All n  290
Age, median (range) 75 (41-95)
Creatinine mol/l median (range) 89 (40-999)
Male gender 122 (42%)
Diabetes mellitus 113 (39%)
Hyperlipidemia 126 (44%)
Hypertension 218 (75%)
CAD 179 (62%)
COPD 51 (18%)
TIA/stroke 44 (15%)
Current smoking 74 (26%)
Primary procedure 198 (68%)
Urgent procedure 163 (56%)
Indication for surgery
Rest pain 120 (41%)
Ulcer or gangrene 170 (59%)
CAD, Coronary artery disease; COPD, chronic obstructive pulmonary dise
*Student t-test for continuous variables, 2 test for categorical variables.59%). In the arm vein group, more than two-thirds (70.2%)of procedures were for ischemic ulcer or gangrene, whereas
in the prosthetic group, the main indication was ischemic
rest pain (51.3%) (Table I). The most common inflow
artery in both groups was the common femoral artery,
63.8% and 72.5%, respectively (Table II). In the arm vein
group, the number of infrapopliteal bypasses was signifi-
cantly higher (P  .001). Median runoff score for femoro-
popliteal bypasses was 5.5 and 6.0 in the arm vein and
prosthetic group, respectively. Median runoff score for
infrapopliteal revascularizations was 1.0 in both groups, so
the groups did not differ according to runoff. Prosthetic
grafts were either ePTFE (91.2%) or polyester (8.8%). In
infrapopliteal prosthetic bypasses (n 42), adjunctive vein
Arm vein grafts
n  130
Prosthetic grafts
n  160 P value*
75 (41-95) 75 (42-95) .614
87 (40-999) 89 (40-554) .907
60 (46%) 62 (39%) .205
56 (43%) 57 (36%) .565
65 (50%) 61 (40%) .055
99 (77%) 117 (75%) .644
79 (61%) 100 (64%) .833
17 (13%) 34 (22%) .059
12 (9%) 32 (20%) .011
27 (21%) 47 (30%) .480
81 (62%) 117 (73%) .263
72 (55%) 91 (57%) .725
.000
38 (29%) 82 (51%)
92 (71%) 78 (49%)
A, transient ischemic attack.
Table II. Operative details by graft material
Arm vein grafts
(n130)
Prosthetic grafts
(n160)
Inflow vessel
External iliac artery 3 (3%) 11 (7%)
Common femoral artery 79 (61%) 116 (73%)
Superficial femoral artery 23 (18%) 4 (3%)
Deep femoral artery 2 (2%) 4 (3%)
Above-knee popliteal
artery 8 (6%) 0
Below-knee popliteal
artery 6 (5%) 0
Limb of the
aortofemoral graft 8 (5%) 13 (7%)
Outflow vessel
Above-knee popliteal
artery 7 (5%) 68 (43%)
Below-knee popliteal
artery 20 (15%) 49 (31%)
Anterior tibial artery 22 (25%) 22 (14%)
Posterior tibial artery 21 (16%) 7 (4%)
Peroneal artery 30 (23%) 13 (8%)
Pedal artery 20 (15%) 1 (1%)cuffs were used in 30 cases (17 St Mary’s booth, 12Miller’s
the number of grafts at risk thereafter is too small.
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cuffed prosthesis was used. Arm vein grafts consisted of one
(36.2%), two (43.1%), three (16.9%), or four (3.8%) seg-
ments. Twenty-seven vein grafts (21%) had a poor segment
(usually vein puncture site at antecubital fossa) excised and
replaced by a short piece of LSV or a branch of the GSV.
The perioperative (30 days) mortality rate was 6.2%
(n  8) and 8.7 % (n  14) in the arm vein and prosthesis
group, respectively (P .406). There were 6 (4.6%) and 18
(11.3%) early (30 days) graft failures in the arm vein and
prosthesis group, respectively (P .041), resulting in early
limb loss (30 days) in 6 (4.6%) vs 11 (6.9%) patients (P
0.601).
When the patency calculations for the whole study
population were performed, primary patency at 3 years did
not differ statistically significantly between arm vein grafts
and prosthetic grafts; 31.4% (SE  5.9%) vs 30.3% (SE 
5.4%), P  0.762. Assisted primary patency and secondary
patency at 3 years were clearly better in the arm vein group;
58.1% (SE  6.0%) vs 34.8 (SE  5.7%), P  .002 and
58.6% (SE  6.1%) vs 38.1% (SE  5.9%), P  .005,
respectively. When subjected to multivariate analysis, the
use of prosthetic graft was a significant risk factor for graft
occlusion (odds ratio [OR], 1.76; 95% confidence interval
[CI], 1.05-2.90; P  .031).
In subgroup analysis of femoropopliteal bypasses, there
was a trend toward better patency in the arm vein group,
but the difference was not statistically significant (Fig 1). In
multivariate analysis, the use of prosthetic graft for femo-
ropopliteal bypass was not a significant risk factor for graft
occlusion (OR, 2.14; 95% CI, 0.75-6.13; P  .157).
In a subgroup analysis of infrapopliteal bypasses, pri-
mary patency, assisted primary patency, and secondary pa-
tency rates at 3 years were significantly better in the arm
vein group, 28.3% (SE  6.3%) vs 9.6% (SE  8.1%) (P 
.031), 56.8% (SE  6.6%) vs 10.4% (SE  8.7%) (P 
.000), and 57.4% (SE  6.6) vs 11.2% (SE  9.3%) (P
.000), respectively (Fig 2). When subjected to multivar-
iate analysis, the use of prosthetic graft for infrapopliteal
revascularization was a significant risk factor for graft occlu-
sion (OR, 2.95; 95% CI, 1.41-6.20; P  .004).
At three years, leg salvage and surprisingly also survival
after infrapopliteal bypass were better in the arm vein
group, 75% (SE 4.9%) vs 57.1% (SE 8.8%) (P .005)
and 60.0% (SE  5.0%) vs 39.5% (SE  7.7%) (P  .007),
respectively. Table III summarizes all outcome variables at
1 and 3 years.
The number of vein graft segments did not affect
patency. Primary, assisted primary, and secondary patency
rates at 1 year for single-piece, two-piece and three- or
four-piece arm vein grafts were 61.3%, 49.9%, and 46.3%
(P  .108), 74.4%, 76.7% and 67.1% (P  .759) and
74.7%, 78.2%, and 67.1% (P  0.734), respectively. The
number of four-piece grafts was so small that they were not
analyzed separately.
Runoff score did not seem to have an affect on patency
neither in the arm vein nor in the prosthetic group when
Kaplan-Meier estimates were assessed. Neither was runoffFig 1. In femoropopliteal bypasses. A, primary patency, B, as-
sisted primary patency, andC, secondary patency were better in the
arm vein group than in the prosthetic bypass group. The difference
was not statistically significant (P .524, P .128, and P .451,
respectively). The standard error (SE ) was 10% throughout the
time interval, except in the arm vein group, where SE at 3 years was
10%. Dashed line cutting the curve at 12 months indicates that
grafts at risk thereafter is too small.
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jected to multivariate analysis (OR, 0.42; 95% CI, 0.17-
1.02; P  .056). However, leg salvage was significantly
worse in those femoropopliteal prosthetic bypasses that had
a runoff score of 8 or worse compared with those with a
runoff score of 1-7 (P .000) In femoropopliteal arm vein
grafts, similar difference was not seen. Interestingly, sur-
vival was worse in those patients with poor runoff (score 8
or worse) (P  .000) probably reflecting the severity of
vascular disease of these patients. Similarly, in multivariate
analysis, poor runoff score turned out to be a strong pre-
dictor of death (OR, 5.4; 95% CI, 1.82-16.09; P  .002).
During surveillance, 35 (27.0%) arm vein grafts devel-
oped significant stenosis, which were treated with either
balloon angioplasty (PTA) (n  22) or with open surgical
repair (6 patch angioplasties, 6 interpositions, and 5 distal
extensions of the graft).
DISCUSSION
Despite the exceeding numbers of endovascular proce-
dures performed for CLI, complex and often multiple
infrainguinal surgical reconstructions are still frequently
needed to salvage a leg. Therefore, the need for alternative
conduits has become an increasing clinical problem. Since
1969 when the first lower limb revascularization with arm
vein graft was introduced,20 the use of arm veins as alter-
native conduits has gained some popularity. There are
several series from the past decade reporting excellent long-
term results in infrainguinal bypasses using arm vein as a
conduit.5,15,16,21 The low morbidity related to arm vein
harvest and good long-term patency have even encouraged
some groups5,15,16 to use arm veins as the first alternative
when the ipsilateral GSV is absent. The rationale for this is
the avoidance of wound problems in donor limbs and
preservation of CGSV for subsequent contralateral limb
revascularization or CABG. In contrast to this, our policy is
to use the best available vein graft to treat the problem now.
Therefore, we prefer the contralateral GSV over arm veins
unless there is evidence of advanced ischemia in the donor
limb. This approach can be defended by the observation
that the need for contralateral revascularizations is reported
to be only between 20% and 23%.5,22,23 The rate of subse-
quent CABG after lower limb revascularization is even
lower, between 2% and 3% in 5 years,6,23 as a large number
of patients with CLI already have had coronary revascular-
ization before the lower limb bypass. Improvement in
medical management and huge increase in number of per-
cutaneous coronary interventions is another obvious reason
that CABG is relatively rarely needed in patients with CLI.
There is also evidence that long-term outcome of the
contralateral limb is not compromised with this “GSV first”
approach even among patients with diabetes.6 Further-
more, if there is a need for subsequent contralateral bypass,
arm veins can still be used for that.
Clinical series from the past 25 years have reported arm
vein graft patency and leg salvage rates at 3 years ranging
from 40% to 73% and 63% to 92%, respectively.3,5,13-16,24-29Fig 2. In infrapopliteal bypasses. A, primary patency (P  .031),
B, assisted primary patency (P  .000), and C, secondary patency
(P  .000) were significantly better in the arm vein group. Stan-
dard error (SE) was 10% throughout the time interval. Dashed
line cutting the curve at 12 months indicates that the number ofIn our series, the overall 3-year secondary patency and leg
etwee
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tively) resemble those results. However, our 3-year primary
patency for arm vein grafts is quite low (31%), compared
with 43% to 70% reported by others.5,13-16,21 An explana-
tion for this is the active graft maintenance policy and early
correction of detected graft stenoses with subsequent loss
of primary patency and improved assisted primary patency.
Indeed, our duplex surveillance led to a 27% graft revision
rate with a 3-year assisted primary patency being far better
than primary patency. Armstrong et al21 reported similar
findings with an intervention rate being even higher (48%).
They achieved excellent 91% 3-year assisted primary pa-
tency due to efficient duplex surveillance. Their conclusion
was that arm veins are prone to stenosis development and
that spliced arm veins had the highest (83%) intervention
rate. Yet the effect of vein graft splicing on graft stenosis
development is controversial, as others reporting excellent
results with arm vein grafts did not find any effect of splicing
of the graft to patency rates.5,13-15 Similarly, in the present
series, the number of vein graft segments did not affect
patency. Another explanation for our inferior primary pa-
tency might be the relatively high incidence of urgent
(55%) procedures with less resources for intraoperative
quality control such as completion angiography, angios-
copy, or duplex scanning. The amount of redo bypasses was
also high (38%). In a recent series by Tinder et al,30 redo
bypass was found to be a risk factor to graft revision. Our
early (30-day) graft failure and subsequent amputation
rates for arm vein grafts were quite high, at 4.6%. However,
others6,31 have reported similar rates, when publishing
their series of complex bypasses with a high rate of second-
Table III. Cumulative outcome rates with adjacent standa
and by different outflow distributions
All bypasses (n  290) Femor
130 arm veins 160 prostheses 27 ar
PP
1-year 55.5%  5.2% 59.2%  4.8% 70.3%
3-year 31.4%  5.9% 30.3%  5.4% 43.4%
P  .762
APP
1-year 75.4%  4.4% 63.7%  4.7% 84.0%
3-year 58.1%  6.0% 34.8%  5.7% 63.0%
P  .002
SP
1-year 76.0%  4.4% 66.5%  4.6% 84.0%
3-year 58.6%  6.1% 38.1%  5.9% 63.0%
P  .005
Leg salvage
1-year 85.4%  3.3% 86.8%  2.9% 95.7%
3-year 77.2%  4.2% 79.7%  3.7% 84.7%
P  .631
Survival
1-year 79.9%  3.5% 75.0%  3.4% 85.2%
3-year 61.0%  4.5% 56.5%  4.0% 69.4%
P  .199
APP, Assisted primary patency; PP, primary patency; SP, secondary patency
Mantel-Cox log-rank test was used to assess the significance of differences bary bypasses and multi-segment vein grafts.Despite the superiority of vein grafts, the use of pros-
thetic grafts may be necessary in patients with CLI not
amenable to endovascular procedures and with no available
autologous vein material. In the above-knee popliteal re-
vascularizations, excellent results have been reported with
the use of prosthetic grafts more than 20 years ago.32,33
Yet, according to recent systematic reviews, autologous
bypass should be chosen whenever possible.1-3 ePTFE has
been a popular and widely used prosthetic material for
decades. The superiority of ePTFE was nevertheless ques-
tioned, as a recent randomized study concluded that poly-
ester (Dacron) is at least as durable as or even better than
ePTFE for above-knee bypasses.34 In the infrapopliteal
location, the results of prosthetic bypasses have been only
moderate. A 2003 published meta-analysis of PTFE infrap-
opliteal bypasses35 yielded pooled 3-year primary patency,
secondary patency, and foot preservation rates of 41%, 51%,
and 66%, respectively. In our series, these rates, especially
patency rates, were worse (10%, 11%, and 57%, respec-
tively). The reason for this might be the high proportion of
urgent procedures (57%). The rate of prosthetic graft oc-
clusions seems to be highest during the first months after
surgery.36 Indeed, also in this series, the 30-day prosthetic
graft thrombosis rate was somewhat high, at 11.3%. Reduc-
tion of these early failures has been one of the leading goals
for vascular prosthesis manufacturers when they have de-
veloped technical improvements, such as heparin-coatings.
There are groups reporting promising early results achieved
with heparin-bonded PTFE or heparin-bonded polyester
or pre-cuffed prostheses not only in the femoropopliteal,
but also in the femorocrural location. One-year primary
rrors at 1 and 3 years in both graft material groups overall
iteal bypasses (n  145) Infrapopliteal bypasses (n  145)
ns 118 prostheses 103 arm veins 42 prostheses
.3% 68.8%  5.4% 51.5%  5.9% 32.0%  8.7%
.1% 36.6%  6.5% 28.3%  6.3% 9.6%  8.1%
P  .524 P  .031
% 74.1%  5.1% 73.2%  5.1% 37.9%  9.3%
.7% 42.3%  6.9% 56.8%  6.6% 10.4%  8.7%
P  .128 P  .000
% 76.8%  4.9% 73.9%  5.0% 37.5%  9.0%
.7% 46.0%  7.1% 57.4%  6.6% 11.2%  9.3%
P  .200 P  .000
% 95.3%  2.1% 82.7%  4.0% 60.9%  8.6%
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tively. Similarly, for infrapopliteal bypasses these rates are
between 74% to 75% and 85% to 100%, respectively.9-12
These prostheses may be better than prostheses without
coatings or distal anastomosis modifications, but there are
no randomized controlled trials yet proving that. Our series
included only nine heparin-bonded PTFE bypasses since
these prostheses have been available for clinical use in
Finland since 2004. Therefore, our results are not compa-
rable to results of series using heparin-coated ePTFE pros-
theses.
In the prosthetic group, the perioperativemortality rate
was high (8.7%) reflecting probably the rather high median
age (75 years) and very high incidence of CAD (64%) in this
patient group. One-year mortality in the infrapopliteal
prosthetic bypass group (38%) was clearly higher than
reported in CLI patients in general.36 Considering this and
only poor midterm patency and moderate leg salvage rates,
one could question the rationale of these procedures. Ac-
cording to Wolfe and Wyatt,37 up to 95% of patients with
critical ischemia (tissue loss and/or ankle pressure40mm
Hg) required amputation if treated conservatively. There-
fore, considering this, it is worth performing infrapopliteal
prosthetic bypass as a last resort for limb salvage when
autologous vein material is not available. Furthermore,
continuous improvement in vascular graft technology
should be taken into consideration.
In our series, there was a wide gap between secondary
patency and leg salvage in the prosthetic bypass group.
Statistical significance of this is, however, questionable, as
the number of grafts at risk is rather small after 12 months.
There are two main reasons for this gap. First, subsequent
autologous vein bypasses after occluded prosthetic bypasses
have avoided amputations. Indeed, 65% of those occluded
prosthetic bypasses that did not require amputation were
femoropopliteal bypasses and were reoperated with autol-
ogous vein graft. Twenty-five percent of patients died
within a month after graft occlusion before re-operation or
amputation. The remaining 10% of patients, despite of lost
patency, remained with rest pain or small ulcers and could
have their amputation delayed.
One shortcoming of this study is the different surveil-
lance programs for vein and prosthetic grafts. Only autol-
ogous grafts were included in routine duplex surveillance,
as there is no evidence beyond expert opinions that duplex
surveillance of prosthetic grafts is worthwhile.38,39 This
lack of duplex scanning may have had some influence on
results, as some prosthetic graft occlusion might have been
missed. It also explains why the difference between primary
and assisted primary patency in prosthetic groups is almost
nonexistent and overall patency is relatively poor. Mecha-
nism of failure of prosthetic graft is believed to be anasto-
motic stenosis and subsequent low graft flow and, there-
fore, there might be value in performing duplex to assess
anatomoses during follow-up, despite missing evidence of
its cost-effectiveness. According to a recent study, even
early duplex scanning of infrapopliteal prosthetic grafts
might, however, be important not for detecting focal ste-noses but for characterizing low flow grafts prone to
thrombosis and selecting patients for anticoaculation.40
Another flaw of this study is the absence of routine intra-
operative duplex or angiography, which obviously might
have had an effect on patency. Moreover, there might be
some conduit selection bias, as both arm veins and prosthe-
ses were alternatives in the femoropopliteal region, but at
infrapopliteal bypasses, arm vein was selected whenever not
absent. This is a retrospective analysis and the number of
patients is relatively small.
In our series, there is an overall trend favoring arm vein
conduits over prosthetic grafts in terms of assisted primary
patency and secondary patency. Still, the difference is not
statistically significant in the femoropopliteal location. The
small number (n  27) of femoropopliteal arm vein by-
passes might be one reason for this.
In conclusion, arm vein conduits, even when spliced,
are superior to prosthetic grafts for infrapopliteal bypasses
in patients with CLI. Arm veins are often the last possible
autologous veins for bypass and they are prone to focal
stenoses, so every effort should be put on the surveillance
and maintenance of these “high-risk grafts”. Despite only
moderate patency rates, prosthetic bypasses to infrapopli-
teal arteries are worthwhile as the last means for limb
salvage.
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